Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

Cancer

Volumn 73, Issue 9, 1994, Pages 2432-2443

  Ross, John F ^a   Chaudhuri, Prabir K ^a   Ratnam, Manohar ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

antifolates; chemotherapy; folate receptor; folate binding protein; transport; tumor markers

Indexed keywords

FOLATE BINDING PROTEIN; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID ANTAGONIST; MEMBRANE RECEPTOR; MESSENGER RNA; RECEPTOR SUBTYPE; TUMOR MARKER;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOMA; CELL STRAIN KB; FETUS; FOLIC ACID RECEPTOR ALPHA; FOLIC ACID RECEPTOR BETA; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PLACENTA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA; CARRIER PROTEINS; CELL LINE; CHORION; FETUS; FOLIC ACID; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; KIDNEY; LIVER; LUNG; NEOPLASMS; POLY A; POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RNA; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028301752     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S     Document Type: Article

References (43)

1. Biology of disease: role of folate binding proteins in folate metabolism
2. The biological chemistry of folate receptors
3. The folate receptor allows cells to grow in low concentrations of 5‐methyltetrahydrofolate
4. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles
5. The influence of extracellular folate concentration on methotrexate uptake by human KB cells
6. Studies of the role of a particulate folate‐binding protein in the uptake of 5‐methyltetrahydrofolate by cultured human KB cells
7. Mediated uptake of folate by a high‐affinity binding protein in sublines of L1210 cells adapted to nanomolar concentrations of folate
8. Expression of a folate binding protein in L1210 cells grown in low folate medium
9. Identification of a membrane‐associated folate‐binding protein in human leukemic CCRF‐CEM cells with transport‐related methotrexate resistance
10. Effect of perturbation of specific folate receptors during in vitro erythropoiesis
11. Megaloblastic hematopoiesis in vitro: interaction of anti‐folate receptor antibodies with hematopoietic progenitor cells leads to a cell proliferative response independent of megaloblastic changes
12. Multiple membrane transport systems for the uptake of folate‐based thymidylate synthase inhibitors
13. Growth‐inhibitory effects of 5,10‐dideazatetrahydrofolic acid on variant murine L1210 and human CCRF‐CEM leukemia cells with different membrane‐transport characteristics for (anti)folate compounds
14. Tumor cell sensitivity and resistance to folate analogues: the role of carrier‐ and receptor‐mediated transport systems
15. Growth inhibition by homofolate in tumor cells utilizing a high‐affinity folate binding protein as a means for folate internalization
16. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier‐ and receptor‐mediated transport systems
17. Proteins involved in the transport of folates and antifolates by normal and neoplastic cells
18. The interrelationship of the soluble and membrane‐associated folate‐binding proteins in human KB cells
19. A human membrane‐associated folate binding protein is anchored by a glycosyl‐phosphatidylinositol tail
20. Evidence that the hydrophobicity of isolated, in situ, and de novo‐synthesized native human placental folate receptors is a function of glycosyl‐phosphatidylinositol anchoring to membranes
21. 2+‐dependent protease in human placenta which cleaves hydrophobic folate‐binding proteins to hydrophilic forms
22. The conversion of the human membrane‐associated folate binding protein (folate receptor) to the soluble folate binding protein by a membrane‐associated metalloprotease
23. Influence of folate‐binding protein from bovine milk on the absorption of folate in gastrointestinal tract of rat
24. Purification of folate binding factor in normal umbilical cord serum
25. Folate‐binding protein is a marker for ovarian cancer
26. Cloning of a tumor‐associated antigen:MOv18 and MOv19 antibodies recognize a folate‐binding protein
27. Further observations on the folatebinding factor in some leukemic cells
28. Serum folate binding capacity in leukemias, liver diseases and pregnancy
29. Folate binding protein and the estrogen receptor in breast cancer
30. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues
31. Homologous membrane folate binding proteins in human placenta: cloning and sequence of a cDNA
32. The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA
33. Molecular cloning and characterization of the human folate‐binding protein cDNA from placenta and malignant tissue culture (KB) cells
34. Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl‐phosphatidylinositol
35. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates
36. Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation
37. Amplification of RNA
38. Influence on immunoreactive folate‐binding proteins of extracellular folate concentration in cultured human cells
39. Transfection of a glycosylated phosphatidylinositol‐anchored folate binding protein complementary DNA provides cells with the ability to survive in low folate medium
40. A new folate antimetabolite, 5,10‐dideaza‐5,6,7,8‐tetrahydrofolate is a potent inhibitor of de novo purine synthesis
41. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study